Laidlaw Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-11,336
Closed -$301K 126
2024
Q4
$301K Buy
11,336
+300
+3% +$8.14K 0.13% 140
2024
Q3
$319K Buy
11,036
+467
+4% +$13.6K 0.16% 128
2024
Q2
$296K Sell
10,569
-734
-6% -$20.2K 0.16% 134
2024
Q1
$314K Sell
11,303
-4,111
-27% -$114K 0.18% 133
2023
Q4
$444K Buy
15,414
+2,342
+18% +$70.8K 0.16% 141
2023
Q3
$434K Sell
13,072
-14,103
-52% -$499K 0.14% 167
2023
Q2
$997K Buy
27,175
+1,329
+5% +$51.7K 0.2% 121
2023
Q1
$1.05M Sell
25,846
-2,291
-8% -$98.9K 0.22% 118
2022
Q4
$1.44M Sell
28,137
-1,788
-6% -$85.7K 0.31% 92
2022
Q3
$1.31M Sell
29,925
-3,954
-12% -$192K 0.31% 90
2022
Q2
$1.78M Buy
33,879
+1,208
+4% +$61.6K 0.36% 81
2022
Q1
$1.69M Sell
32,671
-2,859
-8% -$148K 0.28% 98
2021
Q4
$2.1M Buy
+35,530
New +$1.76M 0.34% 79
2021
Q1
Sell
-35,560
Closed -$1.31M 320
2020
Q4
$1.31M Buy
35,560
+12,311
+53% +$452K 0.28% 101
2020
Q3
$810K Buy
23,249
+2,068
+10% +$72.5K 0.36% 78
2020
Q2
$657K Buy
21,181
+1,342
+7% +$45.6K 0.34% 82
2020
Q1
$614K Sell
19,839
-176
-0.9% -$6K 0.4% 74
2019
Q4
$744K Buy
+20,015
New +$713K 0.47% 72

Other funds holding PFE

Laidlaw Wealth Management's PFE Position: Q1 2025 in Review

Laidlaw Wealth Management sold out of Pfizer (PFE) in Q1 2025, closing a stake of 11,336 shares — an estimated $301K sold.

Laidlaw Wealth Management first reported a position in PFE in Q4 2019 and held it in 18 quarters. The position peaked at $2.1M in Q4 2021. 2,930 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

  • Laidlaw Wealth Management reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
  • Laidlaw Wealth Management sold 11,336 Pfizer shares in Q1 2025, an estimated $301K.
  • Laidlaw Wealth Management first reported a position in Pfizer in Q4 2019 and held it in 18 quarters.
  • Laidlaw Wealth Management's Pfizer position peaked at $2.1M in Q4 2021.
  • 2,930 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Laidlaw Wealth Management's 13F filing for Q1 2025, filed 16 May 2025.